Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Modern Africa Today.
Press releases published on May 1, 2025
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
GlobeNewswire
·
May 1, 2025
Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with …
ESGold Appoints Mining Executive Peter Espig to Board of Directors
GlobeNewswire
·
May 1, 2025
VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ESGold Corp. (“ESGold” or the “Company”) (CSE: ESAU | OTCQB: ESAUF | FSE: Z7D) is pleased to announce the appointment of seasoned mining executive and former global investment banker …
Plato Gold Announces Preparations for First Ever Drill Program at Lolita Project, Santa Cruz, Argentina
GlobeNewswire
·
May 1, 2025
Toronto, May 01, 2025 (GLOBE NEWSWIRE) -- Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (FRANKFURT: 4Y7 OR WKN: A0M2QX) (“Plato” or the “Company”) an exploration company with a portfolio of properties in Northern Ontario and Santa Cruz, Argentina is pleased …
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
GlobeNewswire
·
May 1, 2025
LEIDEN, Netherlands …
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
GlobeNewswire
·
May 1, 2025
BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious …
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
GlobeNewswire
·
May 1, 2025
GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the …
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
GlobeNewswire
·
May 1, 2025
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking …
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 1, 2025
– Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and …
Eccogene Appoints Dr. Jai Patel as Chief Medical Officer
GlobeNewswire
·
May 1, 2025
BOSTON and SHANGHAI, May 01, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced the appointment …
BioCryst Appoints Steve Frank to Board of Directors
GlobeNewswire
·
May 1, 2025
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as …
Fortrea Named a Leader in Everest Group’s Pharmacovigilance Operations PEAK Matrix® Assessment 2025
GlobeNewswire
·
May 1, 2025
DURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a “Leader” for pharmacovigilance (PV) operations by Everest Group in its annual …
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewswire
·
May 1, 2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a …
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
GlobeNewswire
·
May 1, 2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the …
Ligand to Participate in May Investor Conferences
GlobeNewswire
·
May 1, 2025
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference ( …
Critical One Secures Valuable Historical Data for Howells Lake Antimony and Gold Discovery Area
GlobeNewswire
·
May 1, 2025
TORONTO, May 01, 2025 (GLOBE NEWSWIRE) -- Critical One Energy Inc. (formerly Madison Metals Inc.) (“Critical One”, or the “Company”) (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that the Company has been successful in tracking down and …
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
GlobeNewswire
·
May 1, 2025
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg …
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
GlobeNewswire
·
May 1, 2025
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic …
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 1, 2025
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025 …
First Atlantic Nickel Featured in Article Highlighting Hydrogen Potential of Newfoundland and Labrador Nickel Deposits
GlobeNewswire
·
May 1, 2025
VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") a Canadian mineral exploration company focused on developing its 100%-owned Atlantic Nickel …
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
GlobeNewswire
·
May 1, 2025
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs …